Organogenesis Shares Jump 20% on Trial Success

Organogenesis Holdings' stock rose about 20% after its PuraPly AM met primary endpoint in a 170‑patient diabetic foot ulcer trial.
The prospective, multi‑center study showed statistically significant wound closure at 12 weeks versus standard care alone.
COO Patrick Bilbo said results bolster clinical evidence and support future coverage policies for the advanced‑wound‑care product.
Organogenesis focuses on Advanced Wound Care and Surgical & Sports Medicine markets, developing patented collagen‑based therapies.